Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for ...

Donation includes open-source system integrity tests for core and SoC certification Unique Breker tests complement existing test setsBreker’s RISC-V SystemVIP will be demonstrated at booth #P4 during ...

Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, ...

Investing.com -- Omeros Corporation (NASDAQ:OMER) stock soared 65% Wednesday after the biotech company announced a major asset purchase and license agreement with Novo Nordisk (NYSE:NVO) for its ...

Six thousand hens range under the solar array on 16ha (40 acres) of former arable land let to egg producers Charlie and Laura ...

Guava leaves, a potent natural remedy, offer remarkable health benefits when consumed on an empty stomach. They aid in weight ...

Dr. Erin Theisen, who co-led the study, said this discovery could help treat many diseases where inflammation is a problem.

A study led by researchers at Queen Mary University of London has found that hormone replacement therapy (HRT) may help ...